Background: Pre-treatment liver tumor localization remains a challenging task for radiation therapy, mostly due to the limited tumor contrast against normal liver tissues, and the respiration-induced liver tumor motion. Recently, we developed a biomechanical modeling-based, deformation-driven cone-beam CT estimation technique (Bio-CBCT), which achieved substantially improved accuracy on low-contrast liver tumor localization. However, the accuracy of Bio-CBCT is still affected by the limited tissue contrast around the caudal liver boundary, which reduces the accuracy of the boundary condition that is fed into the biomechanical modeling process. In this study, we developed a motion modeling and biomechanical modeling-guided CBCT estimation technique (MM-Bio-CBCT), to further improve the liver tumor localization accuracy by incorporating a motion model into the CBCT estimation process.
Introduction
The incidence rate of primary liver cancer is on the rise both in the United States and worldwide (1) . Liver is also an organ highly susceptible to metastasis from other primary cancers (2) . Radiation therapy has become increasingly popular in primary liver cancer and liver metastasis management, especially with the advent of highly-focused stereotactic body radiation therapy (SBRT) (3, 4) . However, the normal liver tissue has long been known for its low tolerance to radiation. The resulting radiationinduced liver disease (5) is very difficult to manage and often progresses to liver failure and death. The effort of optimizing the therapeutic ratio of liver radiotherapy, by escalating the tumor dose while minimizing the radiation damage to surrounding normal liver tissues, is challenged by the motion of liver and liver tumor (6, 7) . Distinct from other motion-affected sites such as lung, the localization of moving liver tumors is further complicated by the low contrast of liver tumors against the liver parenchyma for X-ray cone-beam computed tomography (CBCT) imaging (8, 9) , the technique widely used for on-board patient setup and treatment position verification in radiation therapy. Iodinated X-ray contrast, though frequently applied in radiotherapy simulation for liver tumor contrast enhancement, is rarely used in on-board CBCT guidance due to the additional workload, the timing uncertainty of contrast administration/imaging, and the potential toxicity of the contrast itself. The lack of a reliable, accurate onboard imaging technique for liver tumor localization necessitates large radiotherapy treatment margins to be added beyond the true extension of the disease. A margin up to 1.5 cm is usually added to account for the imaging and setup uncertainty, leading to over-irradiation of surrounding normal liver tissues and preventing further dose escalation to maximize the benefit of radiation therapy.
To improve the liver tumor localization accuracy, recently we developed a biomechanical modeling-guided CBCT estimation technique (Bio-CBCT) (10, 11) on the basis of the 2D-3D deformation technique (12, 13) . Instead of directly reconstructing CBCT images from cone-beam projections, Bio-CBCT estimates the CBCT images by deforming a prior high-quality CT/CBCT image. The deformation vector field (DVF) is iteratively solved by matching 2D cone-beam projections to digitallyreconstructed-radiographs (DRRs) of the deformed 3D prior image. Through this approach, the tumor volume contoured on a prior simulation CT or a prior CBCT can be simultaneously propagated to the new CBCT image by the solved DVF for automatic liver tumor localization, even if manual tumor localization could be visually challenging. Incorporating prior information also helps to improve the CBCT image quality, and reduce the number of conebeam projections need to be acquired for new CBCT to reduce imaging dose. Compared with the traditional 2D-3D deformation technique (12, 13) , the core advantage of Bio-CBCT is that it incorporates the finite-elementanalysis based biomechanical modeling (14) (15) (16) to optimize the intra-liver DVF. For the traditional 2D-3D deformation technique, the intra-liver DVF is usually poor in accuracy due to the limited intra-liver tissue contrast. Bio-CBCT does not rely on the intra-liver tissue contrast for DVF optimization. Instead, it uses biomechanical modeling to discretize the liver into small, connected finite elements. The movements of these elements (intra-liver DVFs) are collectively solved through finite-element-analysis under specified liver material properties and boundary conditions (17) , which is a physics-driven process that has been validated in solving accurate DVFs at low-contrast regions (18) . For the boundary condition, Bio-CBCT uses the DVF at the liver boundary solved by the 2D-3D deformation technique. Compared to intra-liver motion, the motion of the liver boundary, especially its cranial boundary (which has prominent contrast against the lung), can be accurately solved by intensity-driven 2D-3D deformation. The caudal boundary of the liver, on the other hand, is less intra-treatment liver tumor location verification to achieve substantial radiotherapy margin reduction. differentiable from the surrounding organs. Its motion, as a result, is more difficult to solve from limited 2D cone-beam projections (12) . It may introduce errors into the boundary DVF, which will be further propagated into the intra-liver DVF by the finite-element-analysis based biomechanical modeling.
Keywords
To further boost the DVF accuracy at the caudal liver boundary, in this study we introduced principalcomponent-analysis (PCA) based motion modeling to model the liver boundary motion from patient-specific 4D-CT imaging sets (19, 20) . By motion modeling, we introduced another constraint to improve the accuracy of the caudal liver boundary DVF, by exploiting its implicit correlation with the DVF at the cranial liver boundary. The combined motion modeling and biomechanical modelingguided CBCT estimation technique (MM-Bio-CBCT), was compared with the traditional 2D-3D deformation technique, the 2D-3D deformation technique with motion modeling, and the Bio-CBCT technique. We performed simulation studies using both the extended-cardiac-torso (XCAT) phantom images and real liver patient images. Quantitative metrics including the DICE coefficient (21) and the center-of-mass-error (COME) (20) were evaluated to gauge the performance of different techniques. Motion variations were simulated in the XCAT study to evaluate the robustness of MM-Bio-CBCT towards motion pattern changes between motion modeling and actual CBCT acquisition (22) . Different numbers of cone-beam projections were also used in the patient study to evaluate the potential of MM-Bio-CBCT in imaging dose reduction.
Methods

General workflow of MM-Bio-CBCT
The MM-Bio-CBCT technique is developed on the basis of the traditional 2D-3D deformation technique, sharing the core idea of estimating a new CBCT volume from deforming a prior CT/CBCT volume based on 2D projection matching. The MM-Bio-CBCT technique, however, substantially augments the traditional 2D-3D deformation technique by introducing motion modeling and biomechanical modeling. The general workflow of the MM-Bio-CBCT technique is shown in Figure 1 . Note that the workflow applies to both 3D-CBCT and 4D-CBCT estimations. For 4D-CBCT, the CBCT image and the DVF of each phase are solved independently in the same way as 3D-CBCT, using phase-sorted cone-beam projections. Details of the 2D-3D deformation, motion modeling and biomechanical modeling steps are described below.
2D-3D deformation
The 2D-3D deformation technique uses an intensity-driven approach to solve the DVFs. It optimizes the DVFs such that the 2D DRRs of the deformed 3D prior CT/CBCT volume will match the acquired 2D cone-beam projections ( Figure 2 ). In this study we used the sum-of-squareddifferences metric to measure the similarity between the DRRs and the cone-beam projections. Correspondingly, the DVF is solved via a dual-direction optimization scheme as shown in Eq. 
v denotes the forward DVF which deforms the CT/ CBCTprior volume (u prior ) to estimate the new CBCT. It will also deform the prior liver tumor contours onto the new CBCT for automatic liver tumor localization. v inv , on the other hand, denotes the inverse DVF which deforms the new CBCT back to the CT/CBCT prior volume. We also need to solve this inverse DVF, since the liver boundary DVF extracted from v inv will serve as the boundary condition for the biomechanical modeling step. v inv and v are inherently connected and could be solved jointly through multiple approaches (23, 24) . In this study we took a simple but effective approach by setting v inv = -v. A and A prior denote the cone-beam projection ray-tracing matrices for the acquired cone-beam projections (P) and the simulated conebeam projections (P prior ) of μ prior , respectively. We defined A = A prior since P prior can be simulated at arbitrary angles. The deformation energy term (19) , E(*), regularizes the DVF smoothness for stable and fast convergence. The weighting factors for the deformation energy term, ω, was empirically set to 0.025 (11) . The gradient of the objective function defined in Eq. [1] can be explicitly computed to feed into convenient optimization routines such as the conjugategradient optimization scheme (13, 19) , which was employed in this study. The 2D-3D deformation technique is built purely on projection intensity matching for DVF optimization. For regions with limited intensity variations such as intra-liver regions or caudal liver boundaries, the DVFs may not be accurately solved. In addition, the number of unknown DVF variables is three times the number of the CBCT image voxels. Such a great amount of unknowns leads to an ill-posed optimization problem that can be easily trapped at local optima, and necessitates further dimension reduction and regularization.
Motion modeling
To improve the DVF accuracy at low-contrast caudal liver boundaries, and to reduce the number of unknowns in the DVF optimization, we introduced motion modeling into the MM-Bio-CBCT estimation scheme. Compared with the traditional 2D-3D deformation technique, motion modeling views the DVF as a linear combination of several extracted motion modes (19, 20, 25) . Instead of solving the whole DVF voxel-by-voxel, it solves the linear coefficients of several known motion modes to achieve substantial dimension reduction. In this study, we used a similar PCA based motion modeling strategy as that employed in (19, 20) . The general workflow of the motion modeling step has been depicted in Figure 3 . In detail, for each liver patient, MM-Bio-CBCT learns a liver boundary motion model from his/ her own prior 4D-CT/4D-CBCT imaging set. In radiation oncology, 4D-CT is frequently acquired for liver patients during treatment simulation to study the liver and liver tumor motion to customize motion management strategies. On each phase image of a selected 4D-CT/4D-CBCT, we manually contoured the whole liver volume and densityoverrode the liver to a high Hounsfield Unit number to enhance the contrast of its boundary against surrounding normal tissues/organs, especially for the caudal boundary, to allow boundary-focused motion modeling. Using one phase as the reference phase (usually the end-inspiration or the end-expiration phase due to their relative stability and limited motion artifacts), we deformed the reference phase image to all the other phase images to reveal the motion patterns of the liver volume, via the Demons deformable registration algorithm (26) . Note that since the motion model is built on the reference phase, all the following 2D-3D deformation and biomechanical modeling steps should also use the same reference phase volume as the prior image for the deformation-driven CBCT estimation. The resulting inter-phase DVFs obtained from the deformable registration are subsequently processed through the PCA (25) to train a motion model that represents the key liver motion modes, especially at the caudal liver boundary. The motion model can be mathematically expressed as:
Same as Eq. [1] , v denotes the forward DVF that deforms the prior image to the new CBCT image. The motion model, however, decouples v into several subcomponents, including v 0 ave and 0 j v  . By principal component analysis, v 0 ave is the mean DVF of all inter-phase DVFs. 0 j v  denotes the extracted principal components ranked by their relative importance. N denotes the total number of principal components used to construct the motion model. Same as the previous studies (19, 20) , we used N=3 as 3 principal components prove sufficient to capture the motion patterns, and using more components could adversely affect the modeling accuracy by introducing more noises and local DVF errors. Correspondingly, w j (j=1, 2, 3) are the weightings for each principal motion mode 0 j v  . Replacing the term v in Eq. [1] by Eq. [2] reduces the number of unknowns to 3*3 (Note that w j is a vector denoting three canonical directions, x, y and z) and allows fast DVF optimization using the same conjugate-gradient algorithm as the 2D-3D deformation.
In the above motion modeling framework, the liver boundary motion is successfully captured by manual liver contouring, density-overriding, and deformable registration. An implicit correlation has been established between the cranial and caudal liver boundary motion for each patient in the extracted motion modes. When MM-Bio-CBCT applies the learnt patient-specific motion model to estimate a DVF using Eq. [2] , the implicit correlation between cranial and caudal liver boundary motion will generate more accurate DVFs at the caudal liver boundary, even if the deformation is mainly driven by the high contrast region in the cranial liver boundary.
However, the motion modeling step is only a coarse estimation of the overall liver volume motion with poor intra-liver DVF accuracy. Based on the motion modeling-derived DVF, further 2D-3D deformation and biomechanical modeling are needed to fine-tune the overall DVF especially for that within the liver.
Finite element analysis-based biomechanical modeling
There are multiple models for soft tissue biomechanical modeling and currently no 'gold-standard' exists (14, 27, 28) . To model the liver, we used the Mooney-Rivlin material model, a hyper-elastic biomechanical model often applied towards modeling biological soft tissues (14, 29) . The deformation of the Mooney-Rivlin material is governed by the strain energy density function:
In Eq. [3] , the first two terms quantify the change of the Mooney-Rivlin material's shape towards stress. The third term quantifies the change of the material's volume towards stress. 1 I  , 2 I  and J are DVF derivatives, and c 1 , c 2 and K denote the corresponding material parameters for them. We use c 1 = c 1 = 0.135 kPa and K = 27 kPa as the material parameters, which were empirically determined from a previous study (11) . As shown in Figure 4 , the biomechanical modeling of liver involves a three-step process: (I) liver model generation from the prior image at the reference phase; (II) boundary condition and material property assignment; and (III) finite-element-analysis for intra-liver DVF optimization. For (I), we extracted the 3D liver contour, generated a In summary, MM-Bio-CBCT uses motion modeling to derive a coarse DVF with enhanced accuracy at the caudal liver boundary, and fine-tunes the DVF with an alternating scheme between 2D-3D deformation and biomechanical modeling (Figure 1) . We found a total of 10 iterations are sufficient for the alternating scheme to achieve convergence, and used it as the convergence criteria.
Evaluation
We used both the digital XCAT phantom and real liver patient images to evaluate the MM-Bio-CBCT technique, and to compare its accuracy with that of the traditional 2D-3D deformation technique, the 2D-3D deformation technique with motion modeling, and the Bio-CBCT technique.
Using the XCAT phantom, we simulated a liver patient 4D-CT set as the prior information, and inserted a 3 cmdiameter spherical liver tumor that moves along with the liver volume. The motion of the XCAT phantom follows a diaphragm curve of 2 cm peak-to-peak amplitude, which controls the superior-inferior motion of all organs and tissues. It also follows a chest wall curve of 1.2 cm peak-to-peak amplitude, which controls the phantom's anteriorposterior motion. We used the 10% phase of the 4D-CT as the reference phase (Figure 1) for motion modeling as well as for the deformation-driven CBCT estimation. To evaluate the robustness of the MM-Bio-CBCT technique towards motion variations between prior and new image acquisitions, we simulated different motion scenarios of the to-be-solved new CBCT images. In detail, three different amplitudes were used for the diaphragm motion curve (1, 2 and 3 cm) as well as for the chest wall motion curve (0.6, 1.2 and 1.8 cm) to simulate new 'gold-standard' 4D-CBCTs of different motion scenarios. From these simulated 'goldstandard' new 4D-CBCTs, we generated 20 phase-specific cone-beam projections at different respiration phases (20%, 50%, 70%, 90%), using the Siddon's ray-tracing technique (30) . The cone-beam projections covered a full 360° scan angle, and contained 512×384 pixels per projection, with each pixel spanning 0.776 mm × 0.776 mm in dimension. With the prior CT image at the reference phase (10%), the derived motion model from the prior 4D-CT set, and the simulated cone-beam projections, we applied the MM-Bio-CBCT technique to estimate CBCT images at different phases of different motion scenarios, and compared the resulting image quality and accuracy with those of other techniques. To evaluate the accuracy of using the solved DVFs for automatic liver tumor localization, we contoured the 'gold-standard' liver tumors from the simulated 'gold-standard' CBCT images via intensity thresholding, and calculated the DICE coefficient and the COME metrics between these 'gold-standard' contours and DVF-propagated liver tumor contours. 
The V def symbol denotes the deformed liver tumor contour propagated by the solved DVFs and the V GS symbol denotes the liver tumor contoured on the 'gold-standard' image. A larger DICE coefficient indicates better match and higher tumor localization accuracy, with the optimal value being 1.
As shown in Eq. [5] , COME calculates the Euclidean distance between the center-of-mass of the propagated liver tumor and that of the 'gold-standard' liver tumor, an important metric gauging the accuracy of using the automatically-localized tumor contour for radiotherapy treatment guidance.
In addition to the XCAT study, we performed additional simulation studies using real liver patient 4D-CT images. Three liver patient images were obtained from the openaccess ITK medical image open library (http://midas. kitware.com/community/view/47). All of the 4D-CTs were contrast-enhanced, such that the liver tumors can be manually contoured as the 'gold-standard' to evaluate DVFpropagated liver tumor contours. For the real liver patient images, we applied the 'leave-one-out' strategy by dividing the 10-phase 4D-CT of each patient into two groups: one of nine phases (10-40%, 60-100%) as a subset for motion modeling, and the remaining one phase (50%) was used as the new 'gold-standard' CBCT image for evaluation. Similar to the XCAT study, we used the 10% phase image from the sub-4D-CT-set as the reference phase for motion modeling and deformation-driven CBCT estimation. For the patient study, different numbers of limitedview projections were simulated [5, 10, 20] to evaluate the potential of MM-Bio-CBCT in imaging dose reduction. Figure 5 compares the liver boundary deformation accuracy between Bio-CBCT and MM-Bio-CBCT techniques. The cranial liver boundaries, as marked by the upper dashed line, matched well between Bio-CBCT, MM-Bio-CBCT and 'gold-standard' CBCT images. The finding demonstrates that with high-contrast intensity information at the cranial liver boundary, the boundary DVF can be accurately solved by intensity-driven techniques. However, tracing down inferiorly, it becomes evident that the lower liver boundary is not well deformed by Bio-CBCT, as pointed out by the markers and indicated by the dashed lines. The results show that the limited contrast at the caudal liver side failed to deform the liver boundary accurately by intensity-based techniques. Using motion modeling, MM-Bio-CBCT improves the deformation accuracy at the caudal liver side, as shown in Figure 5 , which helps to further improve the accuracy of biomechanical modeling in solving intra-liver DVFs. Figure 6 compares the reconstructed/estimated CBCT images and the 'gold-standard' CBCT images. The zoomed-in display focuses on the tumor area to compare the accuracy of DVF-propagated liver tumors. It is evident that using only 20 cone-beam projections, the CBCT images reconstructed by the clinical Feldkamp-Davis-Kress (FDK) algorithm (31) contain excessive artifacts and the tumor information has been smeared out. The deformation-driven techniques, on the other hand, preserve 
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the high-quality HU information from the prior image with no streak artifacts. Nonetheless, based on pure projection intensity matching, the 2D-3D deformation technique fails to deform the intra-liver tumor to its correction location. The 2D-3D deformation technique with motion modeling also fails to correctly localize the low-contrast liver tumor.
Using biomechanical modeling to boost DVF at lowcontrast regions, the Bio-CBCT technique generates better matched liver tumors to 'gold-standard', however not as accurate as the MM-Bio-CBCT technique. MM-Bio-CBCT technique deforms the low-contrast liver tumor to well match with the 'gold-standard', by combining motion modeling with biomechanical modeling. Figure 7 shows multi-phase images solved by MM-Bio-CBCT for the XCAT study, with corresponding 'goldstandard' multi-phase CBCT images shown as reference. The solved tumor motion trajectory by MM-Bio-CBCT matches well with that in the reference images. Figure 8 presents the quantitative evaluation results for the XCAT study. Each boxplot contains 12 data points, featuring the three simulated motion scenarios, and the four CBCT phases (20%, 50%, 70%, 90%). The average (± SD) DICE coefficients for 0 DVF (no deformation), 1 mm) , respectively. In Figure 8 , two outliers exist for the MM-Bio-CBCT results, one for phase 50% (DICE: 0.61, COME: 7.9 mm) and the other for phase 70% (DICE: 0.77, COME: 4.6 mm). Both cases are from the motion scenario of relatively large diaphragm curve amplitude (3 cm) and chest wall curve amplitude (1.8 cm). These two cases are particularly challenging, since the liver tumor volume in the prior image is far apart the liver tumor volumes in the 'gold-standard' new CBCT images after the large increase of motion amplitudes, with center-of-mass distance reaching ~3 cm and with minimum volume overlap (DICE ~0). As shown in Table 1 , MM-Bio-CBCT provides consistently more accurate DVFs to propagate the prior liver tumor contours to match the best with the 'goldstandard'. Increasing the number of projections generally improves the accuracy of automatic liver tumor localization, especially for the 2D-3D deformation technique and the Bio-CBCT technique. For 2D-3D deformation with motion modeling, and for MM-Bio-CBCT, the improvements are not substantial. It is caused by the use of motion modeling, which achieves substantial parameter dimension reduction to allow DVF optimization by using only a few projections. Thus, increasing the number of projections will not substantially improve their results. For 2D-3D deformation with motion modeling, even though the motion modeling 
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Discussion
Liver tumor localization has been a challenging task for radiotherapy, even after the substantial developments and improvements of X-ray-based imaging guidance techniques in past decades. The radiotherapy treatments usually have to rely on surrogates to localize the liver tumor, either a high-contrast anatomical structure close to tumor (for instance, diaphragm, or a liver cyst), or several implanted high contrast fiducial markers (6) . However, these surrogates suffer from either the lack of motion correlation with the liver tumor, or from invasiveness and potential surrogate migrations, or both. In this study, we took a different approach to localize the liver tumor. Instead of directly locating the tumors on the X-ray image via visual clues, we developed a new CBCT estimation technique to solve DVFs to morph a prior high quality CT/CBCT image to the new CBCT image, which naturally transfers the liver tumor contours from the prior image to the new image for automatic liver tumor localization. The developed MM-Bio-CBCT technique combines 2D-3D deformation, principal-component-analysis based motion modeling, and finite-element-analysis based biomechanical modeling to solve DVFs of high accuracy for tumor localization. The use of motion modeling not only achieves substantial parameter dimension reduction for fast optimization, but more importantly solves accurate DVFs at the caudal liver boundary where the image contrast could be insufficient to drive accurate DVF optimization ( Figure 5) . The accurate liver boundary DVF, input as the boundary condition for finite-element-analysis based biomechanical modeling, further improves the intra-liver DVF to accurately localize the liver tumor. Both the motion modeling and the biomechanical modeling steps are needed to achieve the best liver tumor localization accuracy, as evidenced in the study results comparing different techniques ( Figure 6 , Figure 8 , Table 1 ). Using as few as 5 projections, the MM-Bio-CBCT technique can achieve an average tumor localization accuracy of ~2 mm, which allows substantial margin reduction to reduce the toxicity of current liver radiotherapy. It also opens up an avenue for further dose escalation to explore the full potential of advanced treatment techniques like liver SBRT. Though developed for liver, the MM-Bio-CBCT technique can also be applied towards other sites where accurate tumor localization might be challenging, such as the kidney. By altering the amplitudes of the motion curves, the XCAT study evaluates the robustness of different techniques towards motion variations. The MM-Bio-CBCT technique remains the most accurate technique, with the lowest localization errors among all. However, when the motion variation causes significant deformations of the new CBCT compared to the prior image, the localization error of MM-Bio-CBCT also increases considerably. It could be caused by the limitation of motion modeling, which works on a prior 4D imaging set and may fail to predict new motion patterns much different from the prior motion patterns. To solve this problem, we could use patient breathing coaching or abdominal compression, to regularize the patient breathing motion to achieve shallower, more reproducible liver motion such that the motion model will remain valid throughout the treatment course. A more robust motion modeling technique that is able to account for large motion variations will also be investigated in future. Another interesting finding, as shown in Table 1 , is that the accuracy of MM-Bio-CBCT is less dependent of the number of projections used in CBCT estimation. The use of motion modeling allows us to use a limited number of projections for DVF optimization, since there are only 9 unknowns to be solved in the motion model (Eq. [2] ). If the motion pattern is similar between different image acquisitions, we can use an extremely limited number of projections, potentially just one single projection (32), to achieve real-time liver tumor localization for treatment monitoring and tumor tracking. The motion modeling steps of MM-Bio-CBCT, including the liver density overriding, the Demons registration and the principal component analysis, are streamlined and fully automatic. The other steps including 2D-3D deformation, biomechanical modeling and finite element analysis are also fully automatic. The liver segmentation step of this study is manually performed on 4D-CT sets. It is an off-line process that can be done any time after the 4D-CT acquisition and does not take patient on-line treatment time. In addition, there are many studies on automatic liver segmentation with very encouraging results (33) (34) (35) (36) . By introducing automatic liver segmentation into our algorithm, MM-Bio-CBCT can be made fully automatic to remove the needs of human input and satisfy the clinical needs of convenience and efficiency. Currently, for MM-Bio-CBCT we used a semi-graphic processing unit (GPU)-accelerated scheme, which takes ~20 minutes when using 5 projections for estimation. Further acceleration is warranted in future studies to render the algorithm more clinically applicable.
In this study, we simulated the cone-beam projections from the XCAT phantom images and real patient images using the ray-tracing technique, an approach widely applied in previous studies (12, 13, 19) . Using simulated images for evaluation allows us to have the 'gold-standard' for quantitative evaluation. In future studies, a more realistic simulation scheme like the Monte-Carlo approach should be used instead to further evaluate the robustness of the MM-Bio-CBCT technique in the presence of degrading signals including scatter, noise and other imaging artifacts (11, 37) . There are multiple previous studies investigating different techniques to reduce these signals (38, 39) , and one of our recent developments by using convolutional neural networks also demonstrated encouraging results in removing these degrading signals (40) . Real clinical projections are also warranted to be evaluated, provided that adequate 'gold-standard' can be obtained for evaluation. For instance, we can use implanted radiopaque fiducial markers near the tumor as the 'gold-standard' to crossevaluate the MM-Bio-CBCT technique, provided that the markers are sufficient in number to reduce the effects of marker migration, and they are fairly close to the tumor to demonstrate actual tumor motion.
In this study, we used prior 4D-CT sets to provide the information to establish motion models. However, sometimes the 4D-CT or 4D-CBCT image quality can be low with artifacts in the abdominal region that may negatively impact clinical applications. The motion modeling algorithm employed in this study is to some extent robust to the image quality issues, since the motion model is derived from density-overridden 4D liver volumes. By density-overriding, intra-liver artifacts can be removed. In addition, the motion model is intended to capture the liver boundary motion and the inherent motion correlation, thus artifacts exterior to the liver boundary may not pose significant issues either. Nonetheless, cautions should still be taken when selecting the reference phase image from 4D-CT/4D-CBCT for motion modeling and deformationdriven CBCT estimation, since imaging artifacts may be passed along from this prior image onto the estimated CBCT images. Thus, it is recommended to select the endinspiration or the end-expiration phase as the reference phase due to their relative stability and limited motion artifacts. For scenarios where the patient breathing is very irregular that substantially degrades the image quality of even the end-inspiration and end-expiration phases, we could use coaching or audio-visual feedback systems to regularize patient breathing (41) .
In radiotherapy, 4D-CT is often acquired for liver patients to assess their motion to customize the motion management techniques. For some patients, for instance those receiving breath-hold radiotherapy treatments, a prior 4D-CT/ 4D-CBCT may not be available for motion modeling. Future studies are warranted to develop techniques to tailor to these patients, where an atlas-based approach or a generalized motion model might be used instead to improve the DVF accuracy at the caudal liver boundary.
